Dr Jon Ackroyd

Dr Jon Ackroyd, Clinical Research Physician, Principal Investigator. Dr.

Dr Firas Almazedi

Dr Almazedi is a medically qualified physician and Approved Principal Investigator with extensive experience in early‑phase clinical trials, including First‑in‑Human (FIH) studies.

Dr Som Menakuru

Dr Som Menakuru, Medical Director and Principal Investigator. Dr Menakuru qualified in Hyderabad, India. He holds the Diploma in Pharmaceutical Medicine and the Certificate of Completion of Training in this discipline.

Multiphase Clinical Research Unit (Phase I–IV)

Dong Yang, PhD, DABT, RAC​

Dong Yang is Head of Regulatory Affairs at Fortrea China with more than 20 years of experience in drug development and regulatory affairs, supporting IND-, NDA-, and BLA-enabling programs.

Carla Sterk, MPharm​

Carla Sterk is a pharmacist by training and a registered Qualified Person (QP) with more than 30 years of experience in global regulatory affairs, including the last 11 years at Fortrea and its legacy organizations, Labcorp Drug D

Kristina Davis, PhD​

Kristina Davis is a Director in Fortrea’s PaCE Team, which assists client companies with gathering patient-focused validity evidence and measurement regulatory strategy within the context of clinical development in the US and Euro

Lesley Reeve, PhD, MSc Reg Aff​

Lesley is a Senior Director of Nonclinical Regulatory Strategy within Fortrea’s Product Development and Market Access Consulting team.

Audrey Finesso, PharmD, MSc​

Dr. Audrey Finesso is a Global Senior Director and Clinical Regulatory Strategist at Fortrea with more than 25 years of experience in regulatory affairs and drug development.

Michelle Dawson, BSc (Pharm), PhD​

Michelle Dawson is a Senior Director in the Product Development Consulting team at Fortrea, based in the UK, with nearly 30 years of experience in pharmaceutical research and development.